Matrix-assisted cocrystallization (MAC) simultaneous production and formulation of pharmaceutical cocrystals by hot-melt extrusion

Journal of Pharmaceutical Sciences

Volumn 103, Issue 9, 2014, Pages 2904-2910

  Boksa, Kevin ^a   Otte, Andrew ^a   Pinal, Rodolfo ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

cocrystals; continuous manufacturing; crystal engineering; crystallization; dissolution; extrusion; formulation; matrix; polymers; solid dispersions; supersaturation

Indexed keywords

CARBAMAZEPINE; NICOTINAMIDE; POLYMER; SOLUPLUS; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMER; POLYVINYL DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; GLASS TRANSITION TEMPERATURE; HOT MELT EXTRUSION; HYDROGEN BOND; INFRARED SPECTROSCOPY; MATRIX ASSISTED COCRYSTALLIZATION; MELTING POINT; PARTIAL LEAST SQUARES REGRESSION; PARTICLE SIZE; PRECIPITATION; X RAY DIFFRACTION; CHEMISTRY; DRUG STABILITY; HEAT; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY;

CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; HOT TEMPERATURE; NIACINAMIDE; POLYETHYLENE GLYCOLS; POLYVINYLS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84906256937     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23983     Document Type: Article

References (28)

1. Good DJ, Rodriguez-Hornedo N,. 2009. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des 9: 2252-2264.
2. Schultheiss N, Newman A,. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9: 2950-2967.
3. Remenar JF, Morissette SL, Peterson ML, Moulton B, Macphee JM, Guzman HR, Almarsson O,. 2003. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 125: 8456-8457.
4. Friscic T, Jones W,. 2009. Recent advances in understanding the mechanism of cocrystal formation via grinding. Cryst Growth Des 9: 1621-1637.
5. Zhang GGZ, Henry RF, Borchardt TB, Lou X,. 2007. Efficient co-crystal screening using solution-mediated phase transformation. J Pharm Sci 96: 990-995.
6. Chiarella RA, Davey RJ, Peterson ML,. 2007. Making co-crystals-The utility of ternary phase diagrams. Cryst Growth Des 7: 1223-1226.
7. Chadwick K, Davey RJ, Dent G, Pritchard RG, Hunter CA, Musumeci D,. 2009. Cocrystallization: A solution chemistry perspective and the case of benzophenone and diphenylamine. Cryst Growth Des 9: 1990-1999.
8. Shan N, Toda F, Jones W,. 2002. Mechanochemistry and co-crystal formation: Effect of solvent on reaction kinetics. Chem Commun 2372-2373.
9. Friscic T, Jones W,. 2007. Cocrystal architecture and properties: Design and building of chiral and racemic structures by solid-solid reactions. Faraday Disscuss 136: 167-178.
10. Nehm SJ, Rodriguez-Spong B, Rodriguez-Hornedo N,. 2006. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst Growth Des. 6: 592-600.
11. Medina C, Daurio D, Nagapudi K, Alvarez-Núñez F,. 2009. Manufacture of pharmaceutical co-crystals using twin screw extrusion: A solvent-less and scalable process. J Pharm Sci 99: 1693-1696.
12. BASF. 2010. Technical information-Soluplus. BASF SE, Care Chemicals Division. Pharma Ingredients and Services. Limburgerhof, Germany (www.pharma-ingredients.basf.com) 1-8.
13. Ng YC, Yang Z, McAuley WJ, Qi S,. 2013. Stabilisation of amorphous drugs under high humidity using pharmaceutical thin films. Eur J Pharm Biopharm 84: 555-565.
14. Steiner R,. 2003. Extruder design. In Pharmaceutical extrusion technology;, Ghebre-Sellassie I, Martin C, Eds. New York: Marcel Dekker, Inc., pp. 17-36.
15. Seefeldt K, Miller J, Alvarez-Núñez F, Rodríguez- Hornedo N,. 2007. Crystallization pathways and kinetics of carbamazepine- nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy and calorimetry studies. J Pharm Sci 96: 1147-1158.
16. Fleischman SG, Kuduva SS, McMahon JA, Moulton B, Bailey Walsh RD, Rodríguez-Hornedo N, Zaworotko MJ,. 2003. Crystal engineering of the composition of pharmaceutical phases: Multiple-component crystalline solids involving carbamazepine. Cryst Growth Des 3: 909-919.
17. Wold S, Ruhe A, Wold H, Dunn WJ,. 1984. The collinearity problem in linear regression. The partial least squares (pls) approach to generalized inverses. SIAM J Sci. Stat. Comput. 5: 735-743.
18. Geladi P, Kowalski BR,. 1986. Partial least-squares regression: A tutorial. Anal Chim Acta 185: 1-17.
19. Wold S, Sjostrom M, Eriksson L,. 2001. Pls-regression: A basic tool of chemometrics. Chemom Intell Lab Sys 58: 109-130.
20. Salari A, Young RE,. 1998. Application of attenuated total reflectance ftir spectroscopy to the analysis of mixtures of pharmaceutical polymorphs. Int J Pharm 163: 157-166.
21. Tobias RD,. 1995. An introduction to partial least squares regression. Analysis 24: 1250-1257.
22. Himes VL, Mighell AD, De Camp WH,. 1981. Structure of carbamazepine: 5h-dibenz b.F azepine-5-carboxamide. Acta Cryst 37: 2242-2245.
23. Porter WW, Elie SC, Matzger AJ,. 2008. Polymorphism in carbamazepine cocrystals. Cryst Growth Des 8: 14-16.
24. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A,. 2006. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res 23: 1888-1897.
25. Jung M-S, Kim J-S, Kim M-S, Alhalaweh A, Cho W, Hwang S-J, Velaga SP,. 2010. Bioavailability of indomethacin-saccharin cocrystals. J Pharm Pharmacol 62: 1560-1568.
26. Noyes AA, Whitney WR,. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc 19: 930-934.
27. Thommes M, Ely DR, Carvajal MT, Pinal R,. 2011. Improvement of the dissolution rate of poorly soluble drugs by solid crystal suspensions. Mol Pharm 8: 727-735.
28. Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ,. 2011. Coformer selection in pharmaceutical cocrystal development: A case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci 100: 2172-2181.